MedTrace Logo

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

NCT00007774 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2009-02-04

No results posted yet for this study

Summary

Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent of patients either fail to respond or only partially respond to conventional antipsychotic agents. Secondary symptoms may be unimproved even in patients who respond to treatment. A variety of adverse events occur in patients receiving currently available agents. The severity of these events contributes to the poor compliance that is observed in this patient population. Olanzapine is a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side effects are minimal.

Conditions

Interventions

DRUG

Haloperidol

DRUG

Olanzapine

Sponsors & Collaborators

Principal Investigators

  • Robert A. Rosenheck, AB MD · VA Connecticut Health Care System (West Haven)

Study Design

Masking
DOUBLE

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-03-31
Primary Completion
2001-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00007774 on ClinicalTrials.gov